產(chǎn)品詳情
簡單介紹：
重組人內(nèi)皮單核細(xì)胞激活多肽II蛋白與其它公司提供的重組蛋白不同，rHuEMAP-II蛋白產(chǎn)品為采用CFS的無細(xì)胞麥胚蛋白合成系統(tǒng)表達(dá)出來的重組蛋白，可表達(dá)出對細(xì)胞有毒性、易被蛋白酶降解的蛋白；并獲得具有良好的可溶性，并有翻譯后修飾、從而部分具有功能的蛋白.同時(shí)獨(dú)有的全自動蛋白純化技術(shù)則簡便高效，將蛋白純化過程中對蛋白的損傷降低到*小程度.重組人內(nèi)皮單核細(xì)胞激活多肽II蛋白（全長序列）產(chǎn)品可用于Western Blot驗(yàn)證、抗體制備、蛋白檢測、ELISA等試驗(yàn)中.
詳情介紹：
重組人內(nèi)皮單核細(xì)胞激活多肽II蛋白
| Synonyms | SCYE1, EMAP-2, Small Inducible Cytokine Subfamily E Member 1 |
| Species | Human |
| Accession | Q12904 |
| GeneID | 9255 |
| Source | Escherichia coli. |
| Molecular Weight | 重組人內(nèi)皮單核細(xì)胞激活多肽II蛋白Approximately 18.2 kDa, a single non-glycosylated polypeptide chain containing 166 amino acids. |
| Quantity | 5μg/20μg/1000μg |
| AA Sequence | SKPIDVSRLD LRIGCIITAR KHPDADSLYV EEVDVGEIAP RTVVSGLVNH VPLEQMQNRM VILLCNLKPA KMRGVLSQAM VMCASSPEKI EILAPPNGSV PGDRITFDAF PGEPDKELNP KKKIWEQIQP DLHTNDECVA TYKGVPFEVK GKGVCRAQTM SNSGIK |
| Purity | > 98 % by SDS-PAGE and HPLC analyses. |
| Biological Activity | 重組人內(nèi)皮單核細(xì)胞激活多肽II蛋白Fully biologically active when compared to standard. The ED50 as determined by the apoptotic effect using serum free human MCF-7 cells is less than 40 ng/ml, corresponding to a specific activity of > 2.5 × 104 IU/mg. |
| Physical Appearance | Sterile Filtered White lyophilized (freeze-dried) powder. |
| Formulation | Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4. |
| Endotoxin | Less than 1 EU/μg of rHuEMAP-II as determined by LAL method. |
| Reconstitution | 重組人內(nèi)皮單核細(xì)胞激活多肽II蛋白We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions. |
| Storage | This lyophilized preparation is stable at 2-8 °C, but should be kept at -20 °C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 °C to -70 °C. Avoid repeated freeze/thaw cycles. |
| 重組人內(nèi)皮單核細(xì)胞激活多肽II蛋白 | |
| SDS-PAGE |
|
| Reference |
1. Awasthi N, Schwarz MA, Schwarz RE. 2010. Cancer Biol Ther, 10: 99-107. 2. Journeay SandSingh B. 2007. Acta Neuropathol, 114: 435; author reply 7-8. 3. Clarijs R, Schalkwijk L, Ruiter DJ, et al. 2003. Invest Ophthalmol Vis Sci, 44: 1801-6. 4. Kayton MLandLibutti SK. 2001. Curr Opin Investig Drugs, 2: 136-8. |
| Background | Endothelial-Monocyte Activating Polypeptide II (EMAP-II) is a tumor derived cytokine that exerts a wide range of activities on endothelial cells, monocytes and neutrophils. EMAP-II inhibits endothelial cell proliferation, vasculogenesis, neovessel formation, and can induce apoptosis. It is also chemotactic towards neutrophils and monocytes and induces myeloperoxidase activity from neutrophils. Of clinical importance, EMAP-II inhibits angiogenesis of vascular beds and suppresses the growth of primary and secondary tumors without affecting normal tissues. Mature EMAP-II is an 18.3 kDa protein, which is synthesized as the C-terminal portion of a biologically inactive precursor protein containing a propeptide of 146 amino acid residues. |
